Press coverage about ICU Medical (NASDAQ:ICUI) has been trending somewhat positive this week, Accern reports. Accern identifies negative and positive press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. ICU Medical earned a media sentiment score of 0.22 on Accern’s scale. Accern also gave media coverage about the medical instruments supplier an impact score of 46.497837154744 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Shares of ICU Medical (NASDAQ ICUI) traded up $2.90 during mid-day trading on Friday, hitting $217.90. The stock had a trading volume of 60,312 shares, compared to its average volume of 127,243. The firm has a market capitalization of $4,328.07, a P/E ratio of 84.31, a PEG ratio of 3.45 and a beta of 0.33. The company has a debt-to-equity ratio of 0.07, a quick ratio of 3.01 and a current ratio of 4.65. ICU Medical has a 1-year low of $127.00 and a 1-year high of $218.45.

ICU Medical (NASDAQ:ICUI) last issued its quarterly earnings results on Thursday, November 9th. The medical instruments supplier reported $1.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.77 by $0.35. The business had revenue of $343.20 million for the quarter, compared to the consensus estimate of $328.56 million. ICU Medical had a return on equity of 4.81% and a net margin of 2.79%. The business’s quarterly revenue was up 253.5% on a year-over-year basis. During the same period in the prior year, the firm posted $1.35 earnings per share. sell-side analysts forecast that ICU Medical will post 3.95 earnings per share for the current year.

ICUI has been the subject of a number of recent research reports. BidaskClub downgraded shares of ICU Medical from a “hold” rating to a “sell” rating in a research note on Wednesday, August 9th. Gabelli reissued a “buy” rating on shares of ICU Medical in a research note on Friday, August 11th. Zacks Investment Research downgraded shares of ICU Medical from a “hold” rating to a “strong sell” rating in a research note on Tuesday, August 15th. Finally, KeyCorp assumed coverage on ICU Medical in a research report on Tuesday, October 17th. They set a “sector weight” rating on the stock. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $232.00.

In other news, Director Robert S. Swinney sold 3,400 shares of the business’s stock in a transaction on Thursday, August 31st. The shares were sold at an average price of $173.98, for a total transaction of $591,532.00. Following the sale, the director now directly owns 20,893 shares of the company’s stock, valued at $3,634,964.14. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Chairman Vivek Jain sold 2,205 shares of the business’s stock in a transaction on Tuesday, October 10th. The shares were sold at an average price of $190.91, for a total transaction of $420,956.55. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 127,247 shares of company stock worth $24,170,158. Insiders own 13.60% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “ICU Medical (ICUI) Earns Daily News Impact Score of 0.22” was originally published by Watch List News and is the property of of Watch List News. If you are viewing this piece on another publication, it was copied illegally and republished in violation of US and international trademark & copyright legislation. The original version of this piece can be read at

About ICU Medical

ICU Medical, Inc is engaged in the development, manufacture and sales of medical devices used in infusion therapy, oncology and critical care applications. The Company’s product line includes needlefree connection devices, custom infusion sets, closed system transfer devices (CSTD) for the handling of hazardous drugs, advanced sensor catheters, needlefree closed blood sampling systems, disposable pressure transducer systems and hemodynamic monitoring systems.

Insider Buying and Selling by Quarter for ICU Medical (NASDAQ:ICUI)

Receive News & Ratings for ICU Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.